The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

Park, Sophie; Horwitz, Steven M.; Foss, Francine M.; Pinter‐Brown, Lauren; Carson, Kenneth R.; Rosen, Steven T.; Pro, Barbara; Hsi, Eric D.; Federico, Massimo; Gisselbrecht, Christian; Schwartz, Marc; Bellm, Lisa A.; Acosta, Mark; Advani, Ranjana H.; Feldman, Tatyana; Lechowicz, Mary Jo; Smith, Sonali M.; Lansigan, Frederick; Tulpule, Anil; Craig, Michael; Greer, John P.; Kahl, Brad S.; Leach, Joseph W.; Morganstein, Neil; Casulo, Carla; Shustov, Andrei R.

doi:10.1002/cncr.31861

Cited by 115 publications

(108 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, while NCCN guidelines suggest that HDT be considered for consolidation in first remission for most aggressive T cell lymphomas except for ALK+ anaplastic large cell lymphomas, only a proportion of patients undergo HDT after initial therapy. In a report from the COMPLETE registry, a prospective outcomes registry of patients with aggressive T cell lymphomas in the United States, Park et al report that of 119 patients with nodal T cell lymphomas who achieved a CR to front line therapy, only 36 (30%) underwent consolidation ASCT . The use of autologous or allogeneic stem cell transplantation in HSTCLs and PGDTCLs has not been well defined in large clinical trials as it has been in the EATLs.…”

Section: Discussionmentioning

confidence: 99%

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas

et al. 2019

Self Cite

View full text Add to dashboard Cite

The T Cell Project was the largest prospective trial to explore the incidence, treatment patterns, and outcomes for T cell lymphomas. The rare subtypes of T cell lymphomas, including hepatosplenic T cell lymphoma (HSTCL), enteropathy associated T cell lymphoma (EATL), and peripheral gamma delta T cell lymphomas (PGDTCLs) are poorly represented in most studies and there is little data regarding treatment patterns. We report results from 115 patients with hepatosplenic (n = 31), enteropathy associated (n = 65), and PGDTCLs (n = 19). While anthracycline regimens were most commonly used as first line therapy, response rates ranged from 20%-40% and were suboptimal for all groups. Autologous stem cell transplantation was performed as a consolidation in first remission in a small number of patients (33% of HSTCL, 7% of EATL, and 12% of PGDTCL), and four patients with HSTCL underwent allogeneic stem cell transplantation in first remission. The progression free survival at 3 years ranged from 28%-40% for these rare subtypes, and the overall survival at 3 years was

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…At a median follow‐up of 2.8 years, the median survival of the transplanted group has not yet been reached, while it is 57.6 months for those without transplant. ASCT was associated a with a hazard ratio of 0.37 and was an independent risk factor for survival . The NCCN guidelines for NHL recommend consideration of ASCT for patients with aggressive PTCL who achieve a CR or PR after primary therapy and are eligible based on age and co‐morbidity .…”

Section: Principles Of Managing Ptcl In 2019mentioning

confidence: 99%

Aggressive T‐cell lymphomas: 2019 updates on diagnosis, risk stratification, and management

Zain

2019

American J Hematol

View full text Add to dashboard Cite

Introduction Aggressive T‐cell lymphomas continue to have a poor prognosis. There are over 27 different subtypes of peripheral T‐cell lymphoma (PTCL) and we are now beginning to understand the differences between the various subtypes beyond histologic variations. Molecular pathogenesis of various subtypes of PTCL Gene expression profiling can help in diagnosis and prognostication of various subtypes including PTCL‐nos and anaplastic large cell lymphoma. In addition, mutational analysis is now being incorporated in clinical trials of novel agents to evaluate various biomarkers of response to allow better therapeutic choices for patients. Targeted therapies There are many targeted agents currently in various stages of clinical trials for PTCL that take advantage of the differential expression of specific proteins or receptors in PTCL tumors. The most promising is the CD30 directed antibody drug conjugate brentuximab vedotin. This has recently been approved by the Food and Drug Administration for the upfront treatment of CD30 expressing PTCLs in combination with cyclophosphamide, doxorubicin, and prednisone chemotherapy. Other notable targets are CD25, CCR4 tag, PI3kinase inhibitors, and JAK/STAT inhibitors. Anaplastic lymphoma kinase (ALK) inhibitors are promising for ALK expressing tumors. Immunotherapies The use of checkpoint inhibitors in the treatment of PTCL is still controversial. The most promising results have been seen in cases of extranodal natural killer cell/T‐cell lymphomas and cutaneous T‐cell lymphomas. For all other subtypes, immune checkpoint inhibitors should be used with extreme caution and only in the context of a clinical trial. Allogeneic stem cell transplant continues to be the curative therapy for most aggressive subtypes of PTCL.

show abstract

“…The data suggested that, for younger patients with MTCL, ASCT remains the preferred consolidation, in particular because patients who relapse after ASCT have some probability of being successfully salvaged with alloSCT. Table 1 [71][72][73][75][76][77][78][79][80][81] shares the published results of ASCT trials in MTCL both in first CR (CR1) and beyond CR1. In conclusion, it appears that ASCT has a role for patients with MTCL in CR1; patients with ALKpositive ALCL also have a favorable outcome with conventional chemotherapy, allowing for the possibility of delaying this strategy until it can be delivered in a salvage setting.…”

Section: The Role Of Autologous Sctmentioning

confidence: 63%

“…More recently, the COMPLETE registry (Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment) reported on a large, multi-institutional, prospective cohort directly comparing the survival outcomes of patients who had nodal MTCL with or without consolidative ASCT in first remission. 73 All histologies of MTCL were included, with the exclusion of large granular lymphocyte leukemias of T-cell origin, precursor T/NK neoplasms, mycosis fungoides, Sezary syndrome, and primary cutaneous CD30-positive disorders. A total of 213 patients were identified as having achieved CR after frontline therapy, 119 of whom had a nodal MTCL, including PTCL-NOS, ALK-negative ALCL, and AITL.…”

Section: The Role Of Autologous Sctmentioning

confidence: 99%

The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management

Marchi

O’Connor

2019

CA A Cancer J Clinicians

View full text Add to dashboard Cite

Historical advances in the care of patients with non-Hodgkin lymphoma (NHL) have been restricted largely to patients with B-cell lymphoma. The peripheral T-cell lymphomas (PTCLs), which are rare and heterogeneous in nature, have yet to experience the same degree of improvement in outcome over the past 20 to 30 years. It is estimated that there are approximately 80,000 and 14,000 cases, respectively, of NHL and Hodgkin lymphoma per year in the United States. As a subgroup of NHL, the PTCLs account for 6% to 10% of all cases of NHL, making them exceedingly rare. In addition, the World Health Organization 2017 classification describes 29 distinct subtypes of PTCL. This intrinsic diversity, coupled with its rarity, has stymied progress in the disease. In addition, most subtypes carry an inferior prognosis compared with their B-cell counterparts, an outcome largely attributed to the fact that most treatment paradigms for patients with PTCL have been derived from B-cell neoplasms, a radically different disease. In fact, the first drug ever approved for patients with PTCL was approved only a decade ago. The plethora of recent drug approvals in PTCL, coupled with a deeper understanding of the molecular pathogenesis of the disease, has stimulated the field to pursue new avenues of research that are now largely predicated on the development of novel, targeted small molecules, which include a host of epigenetic modifiers and biologics. There is an expectation these advances may begin to favorably challenge the chemotherapy paradigms that have been used in the T-cell malignancies.

show abstract

The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

Cited by 115 publications

References 26 publications

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas

Aggressive T‐cell lymphomas: 2019 updates on diagnosis, risk stratification, and management

The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management

Contact Info

Product

Resources

About